Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Dermatological conditions

Addition of baricitinib to mainstay of treatment improves signs and symptoms of atopic dermatitis, study finds

Results from a study in JAMA Dermatology showed that patients with moderate-to-severe atopic dermatitis who received baricitinib achieved better outcomes than those who received placebo.

Atopic dermatitis on hands


After 16 weeks, a higher proportion of patients treated with baricitinib scored 0 (clear) or 1 (almost clear) on the Investigator Global Assessment Scale for Atopic Dermatitis, compared with those in the placebo group

Adding the oral selective Janus kinase (JAK) 1 and 2 inhibitor, baricitinib (4mg), to topical corticosteroid (TCS) treatment significantly improves the signs and symptoms of moderate-to-severe atopic dermatitis (AD), a phase III study in JAMA Dermatology has suggested (30 September 2020)[1].

In the trial, 329 adults with moderate-to-severe AD who had an inadequate response to TCS therapy were randomised to receive either 2mg of baricitinib once daily, 4mg of baricitinib once daily, or placebo, for 16 weeks in combination with TCS.

At week 16, 31% of patients who received 4mg of the drug and 24% of those who received 2mg had achieved a validated Investigator Global Assessment for Atopic Dermatitis score of 0 (clear) or 1 (almost clear), compared with 15% in the placebo group.

Adverse events were reported in 38% of participants in the placebo group compared with 58% and 56% in the 4mg and 2mg groups, respectively. However, serious adverse events affected the same number of participants in the 4mg group as the placebo group.

“Treatment with 4mg of baricitinib in combination with background TCS therapy significantly improved the signs and symptoms of moderate to severe AD in adults compared with placebo, with a rapid onset of action and a safety profile consistent with prior findings from baricitinib clinical development in AD,” the researchers concluded.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2020.20208441

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.